Tevogen Bio to Study its Investigational COVID-19 T Cell Therapy in Immunocompromised Patients Who are Unable to Benefit From Currently Available Prevention or Treatment Options
Tevogen Bio – December 7th, 2022
Tevogen Bio – December 7th, 2022
Tevogen Bio to Develop T Cell Therapies for Treatment of Epstein-Barr Virus Related Cancers and Multiple Sclerosis
Tevogen Bio – December 1st, 2022
Tevogen Bio – December 1st, 2022
Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID
Tevogen Bio – November 22nd, 2022
Tevogen Bio – November 22nd, 2022
Tevogen Bio CEO Dr. Ryan Saadi and Chief Scientific Officer Dr. Neal Flomenberg share White House concerns about emerging COVID-19 variants and their impact on immunocompromised patients, and express the company’s commitment to accelerate development of its investigational COVID-19 therapy
Tevogen Bio – October 27th, 2022
Tevogen Bio – October 27th, 2022